ライフサイエンスコーパス: HIV antigen

1 , 77% to >=1 non-HIV antigen, and 11% to >=1 HIV antigen.

2 maintained by ongoing systemic expression of HIV antigen.

3 nd target cell infection and presentation of HIV antigens.

4 ith increased concentration and affinity for HIV antigens.

5 f these cells had recently been activated by HIV antigens.

6 urable cellular immune responses to multiple HIV antigens.

7 IV) to load human dendritic cells (DCs) with HIV antigens.

8 esponses were specific for canarypox but not HIV antigens.

9 lated with higher proliferative responses to HIV antigens.

10 in comparison to responses against the other HIV antigens.

11 for expressing human immunodeficiency virus (HIV) antigens.

12 with purified human immunodeficiency virus (HIV) antigens.

13 fates of two different heavily glycosylated HIV antigens, a gp120-derived mini-protein and a large,

14 -generation assays by definition detect both HIV antigen and antibody.) The clinical and sociodemogra

15 on of intracellular IFN-gamma in response to HIV antigens and HLA B*57-gag tetramer staining.

16 s (LPR) were measured to various HIV and non-HIV antigens and mitogens using peripheral blood mononuc

17 w abundance antibodies specific to different HIV antigens and rare HIV-specific cells from blood obta

18 Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over t

19 on between CTL activity for each of the four HIV antigens and viral load was observed among individua

20 ersons responded to mitogens, 77% to >=1 non-HIV antigen, and 11% to >=1 HIV antigen.

21 assays: fourth-generation enzyme immunoassay HIV antigen-antibody combination, HIV-1 and HIV-2 rapid

22 nd Prevention PrEP guidelines recommend both HIV antigen/antibody (Ag/Ab) and RNA testing at CAB-LA i

23 arlier in the course of their infection with HIV antigen/antibody (Ag/Ab) combination assays (4th-gen

24 rvention) or to receive the standard of care HIV antigen/antibody assay alone (control).

25 hs) was implemented using a 4(th) generation HIV antigen/antibody assay; HCV screening was offered to

26 The performance of three HIV antigen/antibody combination (HIV Ag/Ab Combo) assay

27 nce of prioritizing in-lab fourth-generation HIV antigen/antibody combination immunoassays in cases o

28 rates of laboratory-based fourth-generation HIV antigen/antibody test among those with polymerase ch

29 results in addition to the standard of care HIV antigen/antibody test result (intervention) or to re

30 s remain stable after multiple passages, and HIV antigens are correctly expressed and released from c

31 s that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines

32 s factor alpha) of CD4+ T cells specific for HIV antigens as well as for adenovirus, Epstein-Barr vir

33 We compared plasma antibody binding to HIV antigens between 51 nontransmitting mother-infant pa

34 T cells responses are associated with lower HIV antigen burden, suggesting that these responses may

35 infected H9 lymphocytic cells were producing HIV antigens by immunofluorescent assay, most lymphocyte

36 sfected with mRNA encoding lysosome-targeted HIV antigen can expand a broad, polyclonal repertoire of

37 activity, proliferative CD4 cell response to HIV antigens, CD8 cell production of macrophage inflamma

38 In the present study we use a model HIV antigen (CN54gp140) conjugated to transferrin (Tf) a

39 nes induced immune responses against a model HIV antigen comparable to electroporation in mice, enhan

40 measured IgG isotypes against four consensus HIV antigens from 2 weeks to 10 years post HIV-1 vaccina

41 For example, self-tumor or HIV antigens genetically fused with proinflammatory chem

42 sis were binding antibody (bAb) responses to HIV antigens (gp120 from strains ZM96, 1086, and TV1; va

43 the IgA antibodies and IgA antibodies to non-HIV antigens had no HIV excretory function.

44 ented LPR of HIV-seropositive persons to non-HIV antigens; however, the effect was greatest for those

45 Addition of IL-12 also enhanced LPR to HIV antigens in 30% of subjects.

46 ced cellular and humoral immune responses to HIV antigens in both groups, though the reduction was gr

47 nv is commonly used as part of a cocktail of HIV antigens in current vaccines.

48 +) patients demonstrated increased basal and HIV antigen-induced expression of the early apoptosis ma

49 ific CD8) and B cell immune responses to the HIV antigens, leading to high antibody titers against gp

50 of persistent herpesvirus vectors to deliver HIV antigens may facilitate the induction of long-term a

51 Thus, CTL responding to different HIV antigens may not be contributing equally to the prev

52 Cytotoxic immunoconjugates targeted to HIV antigens on the cell surface may clear these cells.

53 strong lymphocyte-proliferative responses to HIV antigens or antibodies to many viral epitopes.

54 on using commercial blood tests that measure HIV antigens or antibodies.

55 d explore how rapid tests to directly detect HIV antigens or nucleic acids might alter current approa

56 e of detecting human immunodeficiency virus (HIV) antigens or nucleic acids represent the possibility

57 produce a recombinant biopharmaceutical, the HIV antigen P24.

58 itro assembly system which allows display of HIV antigens, p24-gag, Nef, and an engineered gp41 C-pep

59 by CD4(+) and CD8(+) T cells in response to HIV antigens/peptides in vitro; these effects were cell

60 8 expression affects immune responses to non-HIV antigens, potentially contributing to susceptibility

61 n of IgG specific for selected transmembrane HIV antigens provides a simple and reliable test that is

62 memory T cells to proliferate in response to HIV antigens rather than an absolute loss of circulating

63 However, responses to an HIV antigen remained depressed, and the production of in

64 nal in T cell stimulation assays and induced HIV antigen-specific CD8(+) T cell production of IFN-gam

65 s, adoptive transfer of genetically modified HIV-antigen-specific T cells was safe.

66 ither bulk CXCR5(+) CD4(+) T cells nor other HIV antigen specificities were associated with gp120-spe

67 uction of HIV-suppressive beta-chemokines by HIV antigen-stimulated PBMC was significantly higher in

68 ete cytokines and proliferate in response to HIV antigen stimulation.

69 Env binding antibodies, compared with other HIV antigens (such as p24) or tetanus toxoid.

70 total responses of ELISPOT-forming cells to HIV antigens than do children who are treated later in l

71 ound p24gag (referred to as p24 in the text) HIV antigen through secretory IgA (SIgA) in nasal mucosa

72 ty complex class II (MHC-II) presentation of HIV antigens to CD4 T cells.

73 steria to infect human monocytes and present HIV antigens to CD8 T lymphocytes of HIV-infected donors

74 tem, recombinant constructs encoding several HIV antigens up to 500 amino acids were produced.

75 redirect T and NK cells to target cancer and HIV antigens using DNP-conjugated antibodies as adaptor

76 ducing cells, IL-2 production in response to HIV antigens was diminished during viremia.

77 even though their capacity to proliferate to HIV antigens was preserved only in LTNP.

78 Using HIV antigens, we found that administering a given total

79 In each case, proliferative responses to HIV antigens were rapidly inhibited during viremia.

80 that memory B-cell responses to HIV and non-HIV antigens were superior in early- compared with chron

81 uld be induced to proliferate in response to HIV antigens when costimulation was provided by anti-CD2

82 ell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune par